These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 29308973)

  • 41. Epidermal growth factor receptor: a promising therapeutic target for colorectal cancer.
    Scartozzi M; Pierantoni C; Berardi R; Antognoli S; Bearzi I; Cascinu S
    Anal Quant Cytol Histol; 2006 Apr; 28(2):61-8. PubMed ID: 16637508
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Epidermal growth factor receptor inhibition strategies in pancreatic cancer: past, present and the future.
    Cohenuram M; Saif MW
    JOP; 2007 Jan; 8(1):4-15. PubMed ID: 17228128
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling.
    Chakravarti A; Loeffler JS; Dyson NJ
    Cancer Res; 2002 Jan; 62(1):200-7. PubMed ID: 11782378
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Epidermal growth factor receptor targeted therapies for solid tumours.
    Van den Eynde M; Baurain JF; Mazzeo F; Machiels JP
    Acta Clin Belg; 2011; 66(1):10-7. PubMed ID: 21485758
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Small molecule tyrosine kinase inhibitors in glioblastoma.
    Kim G; Ko YT
    Arch Pharm Res; 2020 Apr; 43(4):385-394. PubMed ID: 32239429
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Epidermic growth factor receptor (EGFR) in glioblastomas: the mechanism of tumorigenesis and its role as a therapeutic target].
    Zahonero C; Sepúlveda JM; Sánchez-Gómez P
    Rev Neurol; 2015 Jul; 61(2):85-93. PubMed ID: 26156444
    [TBL] [Abstract][Full Text] [Related]  

  • 47. EGFR heterogeneity and implications for therapeutic intervention in glioblastoma.
    Eskilsson E; Røsland GV; Solecki G; Wang Q; Harter PN; Graziani G; Verhaak RGW; Winkler F; Bjerkvig R; Miletic H
    Neuro Oncol; 2018 May; 20(6):743-752. PubMed ID: 29040782
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies.
    De Witt Hamer PC
    Neuro Oncol; 2010 Mar; 12(3):304-16. PubMed ID: 20167819
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The future of glioblastoma therapy: synergism of standard of care and immunotherapy.
    Patel MA; Kim JE; Ruzevick J; Li G; Lim M
    Cancers (Basel); 2014 Sep; 6(4):1953-85. PubMed ID: 25268164
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Monoclonal Antibodies in Cancer--Fourth International Congress. EGFR/HER1 antibodies. 3-6 September 2004, Colorado Springs, CO, USA.
    Zhu Z
    IDrugs; 2004 Nov; 7(11):974-6. PubMed ID: 15551165
    [No Abstract]   [Full Text] [Related]  

  • 51. Tyrosine Kinase Inhibitors in Adult Glioblastoma: An (Un)Closed Chapter?
    Aldaz P; Arozarena I
    Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830952
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Melatonin's Antineoplastic Potential Against Glioblastoma.
    Moretti E; Favero G; Rodella LF; Rezzani R
    Cells; 2020 Mar; 9(3):. PubMed ID: 32138190
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A Systematic Review of Glioblastoma-Targeted Therapies in Phases II, III, IV Clinical Trials.
    Cruz Da Silva E; Mercier MC; Etienne-Selloum N; Dontenwill M; Choulier L
    Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33918704
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Development of targeted therapies in treatment of glioblastoma.
    Xu YY; Gao P; Sun Y; Duan YR
    Cancer Biol Med; 2015 Sep; 12(3):223-37. PubMed ID: 26487967
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Repurposing existing agents as adjunct therapies for glioblastoma.
    Purow B
    Neurooncol Pract; 2016 Sep; 3(3):154-163. PubMed ID: 31386097
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies.
    An Z; Aksoy O; Zheng T; Fan QW; Weiss WA
    Oncogene; 2018 Mar; 37(12):1561-1575. PubMed ID: 29321659
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Glioblastoma under Siege: An Overview of Current Therapeutic Strategies.
    Paolillo M; Boselli C; Schinelli S
    Brain Sci; 2018 Jan; 8(1):. PubMed ID: 29337870
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Metformin and temozolomide, a synergic option to overcome resistance in glioblastoma multiforme models.
    Valtorta S; Lo Dico A; Raccagni I; Gaglio D; Belloli S; Politi LS; Martelli C; Diceglie C; Bonanomi M; Ercoli G; Vaira V; Ottobrini L; Moresco RM
    Oncotarget; 2017 Dec; 8(68):113090-113104. PubMed ID: 29348889
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunotherapy for brain tumors: understanding early successes and limitations.
    Lieberman NAP; Vitanza NA; Crane CA
    Expert Rev Neurother; 2018 Mar; 18(3):251-259. PubMed ID: 29322843
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.